New hope for frailest leukemia patients: gentler chemo combo tested
NCT ID NCT02286726
Summary
This study tested a new, packaged form of two standard chemotherapy drugs (CPX-351) for adults newly diagnosed with a fast-growing blood cancer called AML. The patients were older or had other health problems, putting them at high risk of severe side effects from standard treatment. Researchers aimed to find the best dose to control the cancer while minimizing dangerous toxicity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.